Annual Financials for Todos Medical Ltd.
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
- | - | - | 5.21M | 12.23M | |
Sales Growth |
- | - | - | - | 134.88% | |
Cost of Goods Sold (COGS) incl. D&A |
- | 25,650 | 29,643 | 3.85M | 7.88M | |
COGS excluding D&A |
- | - | - | 3.75M | 7.11M | |
Depreciation & Amortization Expense |
24,083 | 25,650 | 29,643 | 96,000 | 763,000 | |
Depreciation |
24,083 | 25,650 | 29,643 | 96,000 | 763,000 | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | - | 15.57% | 12,874.40% | 104.78% | |
Gross Income |
- | (25,650) | (29,643) | 1.36M | 4.35M | |
Gross Income Growth |
- | - | -15.57% | 4,691.30% | 219.91% | |
Gross Profit Margin |
- | - | - | - | 35.60% | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
1.31M | 1.35M | 3.49M | 15.62M | 13.64M | |
Research & Development |
696,444 | 433,534 | 726,056 | 9.84M | 795,000 | |
Other SG&A |
617,087 | 919,694 | 2.76M | 5.79M | - | |
SGA Growth |
- | 3.02% | 157.57% | 348.19% | -12.69% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
1.1M | (925,910) | 4.25M | 6.44M | 601,000 | |
EBIT after Unusual Expense |
(2.44M) | (452,970) | (7.76M) | (20.71M) | (9.89M) | |
Non Operating Income/Expense |
(236,530) | (4,570) | (50,000) | (4.37M) | (591,000) | |
Non-Operating Interest Income |
- | - | - | - | - | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
- | - | 1.04M | 3.5M | 31.18M | |
Interest Expense Growth |
- | - | - | 236.62% | 792.07% | |
Gross Interest Expense |
- | - | 1.04M | 3.5M | 31.18M | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(2.68M) | (457,541) | (8.85M) | (28.57M) | (41.66M) | |
Pretax Income Growth |
- | 82.90% | -1,833.97% | -222.91% | -45.79% | |
Pretax Margin |
- | - | - | - | -340.61% | NA |
Income Tax |
- | - | - | - | - | |
Income Tax - Current Domestic |
- | - | - | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | (2.97M) | (1.2M) | (1.66M) | |
Other After Tax Income (Expense) |
31,950 | - | - | - | - | |
Consolidated Net Income |
(2.64M) | (457,541) | (11.81M) | (29.77M) | (43.31M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(2.64M) | (457,541) | (11.81M) | (29.77M) | (43.31M) | |
Net Income Growth |
- | 82.69% | -2,482.18% | -152.00% | -45.48% | |
Net Margin Growth |
- | - | - | - | -354.16% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(2.64M) | (457,541) | (11.81M) | (29.77M) | (43.31M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(2.64M) | (457,541) | (11.81M) | (29.77M) | (43.31M) | |
EPS (Basic) |
(0.04) | (0.01) | (0.13) | (0.11) | (0.06) | |
EPS (Basic) Growth |
- | 83.75% | -1,875.38% | 10.51% | 44.56% | |
Basic Shares Outstanding |
68.59M | 70.87M | 92.02M | 259.18M | 679.57M | |
EPS (Diluted) |
(0.04) | (0.01) | (0.13) | (0.11) | (0.06) | |
EPS (Diluted) Growth |
- | 83.75% | -1,875.38% | 10.51% | 44.56% | |
Diluted Shares Outstanding |
68.59M | 70.87M | 92.02M | 259.18M | 679.57M | |
EBITDA |
(1.31M) | (1.35M) | (3.49M) | (14.17M) | (8.52M) | |
EBITDA Growth |
- | -3.02% | -157.57% | -306.39% | 39.83% | |
EBITDA Margin |
- | - | - | - | -69.69% | NA |